By Michael Erman SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug
Pfizer CEO Envisions Booming Consumer Market for Obesity Drugs Like Viagra
Pfizer's Ambitious Plans for Obesity Drugs
By Michael Erman
Market Comparison to Viagra
SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.
Investment and Development Strategy
Bourla said that even when the drugmaker was negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs currently dominated by Eli Lilly and Co and Novo Nordisk to get so big, so fast.
Challenges Ahead for Pfizer
"Both Lilly and Novo presented their sales and had significant sales outside the reimbursement system. Basically, outside the U.S., we were calculating very limited sales," Bourla said, speaking to a group of reporters during the J.P. Morgan Healthcare Conference in San Francisco.
"Now we see that this operates almost like Viagra, where people were willing to pay and buy it, although it was not reimbursed at all."
Pfizer developed and sold Viagra, which is now sold mostly as a generic drug, for years, but spun off the business that controls the brand in 2020.
Pfizer has said it does not expect to return to revenue growth until 2029, as it works to develop new blockbuster drugs, including the obesity treatments it picked up in the $10 billion acquisition of Metsera.
The company announced earlier on Monday that it plans to launch 10 different phase 3 studies of obesity compounds from Metsera by the end of the year, including one it launched in November. It bought Metsera for up to $10 billion after winning a bidding war against Novo.
"We are all in on obesity," Bourla said. "We invested. We have good expertise in commercial, good expertise in development and good expertise in discovery."
Pfizer has said it expects the next few years to be bumpy, due to the expiration of patents on key drugs, lower sales from its COVID-19 business and price cuts promised to the U.S. government.
It was the first major pharmaceutical company to sign a deal with the Trump administration to lower the price of its prescription drugs in the Medicaid program in exchange for three years of tariff relief.
Bourla said the government deals, which require drugmakers to offer their new medicines at the same price in the U.S. as overseas, will help companies put pressure on European countries to increase what they will pay for drugs.
"Do you reduce the (U.S.) prices to France's level or stop supplying France? You stop supplying France," Bourla said. "So they will stay without new medicines ... because the system will force us not to be able to accept the lower prices."
(Reporting by Michael Erman; Editing by Jamie Freed)
